Effects of α-tocopherol on an animal model of tauopathies


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2004
Contact PI Name:
Takeshi Ishihara
Contact PI Affiliation:
Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
Co-Authors:
Hanae Nakashima, Osamu Yokota, Seishi Terada, John Q. Trojanowski, Virginia M.-Y. Lee, Shigetoshi Kuroda
Primary Reference (PubMED ID):
Funding Source:
Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT)
Marian S. Ware Alzheimer Program
National Institutes of Health (NIH)
Zikei Institute of Psychiatry
Study Goal and Principal Findings:

We have reported that transgenic (Tg) mice overexpressing human tau protein develop filamentous tau aggregates in the CNS. We overexpressed the smallest human tau isoform (T44) in the mouse CNS to model tauopathies. These tau Tg mice acquire age-dependent CNS pathologies, including insoluble, hyperphosphorylated tau and argyrophilic intraneuronal inclusions formed by tau-immunoreactive filaments. Therefore, these Tg mice are a model that can be exploited for drug discovery in studies that target amelioration of tau-induced neurodegeneration as well as for elucidating mechanisms of tau pathology in various neurodegenerative tauopathies. Oxidative stress has been implicated in the pathogenesis of various neurodegenerative diseases, including tauopathies, and many epidemiological, clinical, and basic studies have suggested the neuroprotective effects of vitamin E in neurodegenerative diseases. To elucidate the role of oxidative damage in the pathological mechanisms of these Tg mice, we fed them α-tocopherol, the major component of antioxidant vitamin E. Supplementation of α-tocopherol suppressed and/or delayed the development of tau pathology, which correlated with improvement in the health and attenuation of motor weakness in the Tg mice. These results suggest that oxidative damage is involved in the pathological mechanisms of the tau Tg mice and that treatment with antioxidative agents like α-tocopherol may prevent neurodegenerative tauopathies.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Dietary Interventions & Supplements
Therapeutic Agent:
alpha-Tocopherol
Therapeutic Target:
Multi Target

Animal Model

Model Information:
Species:
Mouse
Model Type:
Tau
Strain/Genetic Background:
B6D2/F1

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest
Experiment Notes

Number of Premature Deaths: A percentage (6.9%) of T44 mice used in this study died from undetermined causes. This mortality percentage is consistent with previous reports from this group (Ishihara et al., 1999; Neuron 24:751-762).

Outcomes

Outcome Measured
Outcome Parameters
Motor Function
Tail Suspension Test
Histopathology
Axonal Degeneration
Tau Pathology
Biochemical
Brain-Buffer Soluble Tau Protein
Brain-Formic Acid Soluble Tau Protein
Insoluble Tau
Oxidized Proteins
Immunochemistry
8-hydroxy-2'-deoxyguanosine (8-OHdG)
Neurofilament L (NF-L)
Neurofilament M (NF-M)
Neurofilament H (NF-H)
phospho-Neurofilament H (phospho-NF-H)
phospho-Tau
Microscopy
Tau Spheroid
Pharmacokinetics
Drug Concentration-Brain
Drug Concentration-Plasma
Toxicology
Body Weight
Mortality

Source URL: http://alzped.nia.nih.gov/effects-α-tocopherol-animal